Skip to main content
. 2020 Jan 20;10:694. doi: 10.1038/s41598-020-57714-3

Figure 1.

Figure 1

TAK-242 reduces LPS-induced atrophy of C2C12 myotubes. (A,B) Western blot analysis (A) and quantification (B) of MyHC expression in C2C12 myotubes treated for 48 h with vehicle, LPS (1 μg/mL), or LPS and TAK-242 (1 μM). Data in (B) were normalised to β-tubulin protein levels, and the ratio in vehicle-treated control cells was set to 1. N = 5/group. Full-length blots are presented in Supplementary Figure S4. (C) Representative immunofluorescence staining of MyHC in C2C12 myotubes treated as described for (A,B). Scale bar = 100 μm. (D–F) Distribution of myotube widths (D), mean myotube width (E), and fusion index (F) of C2C12 cells treated as described in (A,B). Myotube width was measured as described in the Methods. N = 97–114. The fusion index was calculated from five randomly selected fields as described in the Methods. For all panels, data are presented as the mean ± s.e.m. ***p < 0.001, **p < 0.01, *p < 0.05 vs vehicle control; ###p < 0.001, ##p < 0.01 vs LPS-treated group. P-values were derived from one-way ANOVA followed by Tukey’s honest significant difference test or Kruskal-Wallis test followed by Dunn’s post hoc tests with Bonferroni correction.